Real-world utilization pattern of dydrogesterone in 7287 Indian women with obstetric and gynecological conditions: data from multicentric, retrospective study.

Sunita Tandulwadkar, Mahesh Gupta, Pratima Mittal, Achla Batra, Jaydeep Tank, Sanjay Gupte, Purna Chandra Mahapatra, Jayanthi Reddy, Ashish Kumar Mukhopadhyay, Lila Vyas, Sunita Chandra, Vidya Bhat, Kawita Bapat, Parikshit Tank, Ketan Kulkarni, Onkar Swami

Journal: Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia 2024;46():

PMID: 38765536

Abstract

OBJECTIVE

Despite the literature on dydrogesterone, studies on dydrogesterone utilization patterns are largely lacking in Indian patients.

METHODS

This was a multi-center, retrospective, observational, cross-sectional, and descriptive study across 817 centers in India. Data of patients who received dydrogesterone in past and provided consent for future use of their medical record for research purpose was were retrieved and analyzed.

RESULTS

Data of 7287 subjects (aged 29.55±4.84 years) was analyzed. Threatened abortion was the most common indication for which the subjects received dydrogesterone (46.9%) followed by recurrent pregnancy loss. Polycystic ovary syndrome (PCOS), thyroid disorders and anemia were the most common comorbid conditions and prior pregnancy loss, advanced maternal age and obesity were the most common risk factors seen in subjects who received dydrogesterone. Total 27.5% of subjects received a loading dose of dydrogesterone, and majority (64%) received 40 mg as loading dose. 10 mg dose was used as maintenance or regular dose in 81.4% of the subjects. Twice daily (BID) was the most common dosing frequency (66.6%). The most common concomitant medications being taken by the subjects on dydrogesterone included folic acid (45.1%), iron supplements (30.3%) and calcium and vitamin D3 supplements (25.5%). Another progesterone preparation (oral, injection, vaginal, tubal) other than dydrogesterone was used concurrently in 7.8% of subjects.

CONCLUSION

The study helped to identify the patient population that is benefitted by dydrogesterone and the preferred indications, risk factors, comorbid conditions and concomitant medication used in this patient population at real-life scenario.

© 2024. Federação Brasileira de Ginecologia e Obstetrícia. All rights reserved.

Address: Ashwini Maternity and Surgical Hospital Mumbai India Ashwini Maternity and Surgical Hospital, Mumbai, India.; Gupte Hospital and Centre for Research in Reproduction Pune - Obstetrics and Gynecology PuneMaharashtra India Gupte Hospital and Centre for Research in Reproduction, Pune - Obstetrics and Gynecology, Pune, Maharashtra, India.; Prachee Nursing Home Cuttack India Prachee Nursing Home, Cuttack, India.; J. J. Hospital Hyderabad India J. J. Hospital, Hyderabad, Hyderabad, India.; Vardhman Mahavir Medical College and Safdarjung Hospital New Delhi India Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.; CSS College of Obstetrics Kolkata India CSS College of Obstetrics, Gynae. & Child health, Kolkata, India.; Vyas Clinic JaipurRajasthan India Vyas Clinic, Jaipur, Rajasthan Jaipur, India.; Pushpam Hospital Ahmedabad India Pushpam Hospital, Ahmedabad, India.; Ruby Hall Clinic IVF and Endoscopy Centre Pune India IVF and Endoscopy Centre, Ruby Hall Clinic, Pune, India.; Rajendra Nagar Hospital and IVF Center Lucknow India Rajendra Nagar Hospital and IVF Center, Lucknow, India.; Radhakrishna Multispecialty Hospital BangaloreKarnataka India Radhakrishna Multispecialty Hospital, Bangalore, Karnataka, India.; Bapat Hospital IndoreMadhya Pradesh India Bapat Hospital, Indore, Madhya Pradesh, India, Indore, India.; Emcure Pharmaceuticals PuneMaharashtra India Emcure Pharmaceuticals, Pune, Maharashtra, India.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.